natgillin/translations-raw huggingface dataset:
33.0 5 r-hIL-18BP started to elute at around 28-32% of solution B (see above in bold) and it was completely eluted within 60 minutes (35%B). 
33.0 5 r-hIL-18BP se počinje eluirati kod oko 28-32% otopine B (u prethodnoj tablici masno otisnute vrijednosti) te je potpuno eluiran za 60 minuta (35%B).
said process comprising reducing a compound according to formula (13), or tautomer, or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, 
Postupak za proizvodnju spoja u skladu sa sljedećom formulom (13) ili njegove soli: se, Na gdje RI je vodikova ili dušikova zaštitna skupina, 5
The (S)-(+)-Camphor-10-sulphonic acid salt of Isomer B was prepared and a single crystal was subjected to X-ray crystallographic studies under the following conditions: 
Pripremi se sol (S)-(+)-kamfor-10-sulfonske kiseline Izomera B i jedan kristal se podvrgne kristalografskom proučavanju X-zrakama uz slijedeće uvjete: HR P20090074 T3
a C1-6 alkoxy group, an amino group optionally mono- or di-substituted by substituent(s) selected from 
C1-6 alkoksi-skupina, amino-skupina opcionalno mono- ili di-supstituirana sa supstituentom (supstituentima) odabranom (odabranima) od
formed with a like geometry of said supporting structure (1 A, 1 B), 
- oblikovane sa sličnom geometrijom navedene nosive strukture (1 A, 1B),
The method of claim 1, wherein the metal carbonyl compound comprises an anionic metal carbonyl, preferably: 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što metalni karbonilni spoj sadrži anionski metalni karbonil, izborno:
A slow stream of air or nitrogen was passed over the sample. 
Uzorak je zatim ostavljen 5 minuta pri 300"C. Polagana struja zraka ili dušika išla je preko uzorka.
Composition according to claim 2, characterised in that the concentration of tramadol, or a pharmaceutically acceptable salt thereof, is comprised between 0.5% (w/v) and 2% (w/v), expressed as equivalent concentration of tramadol hydrochloride. 
Pripravak u skladu s patentnim zahtjevom 2, naznačen time što se koncentracija tramadola, ili njegove farmaceutski prihvatljive soli, kreće između 0,5% (tež./vol.) i 2% (tež./vol.), što se izražava kao ekivalentna koncentracija tramadol-hidroklorida.
Typically, transdermal patches comprise an impermeable backing layer, a single pressure sensitive adhesive and a removable protective layer with a release liner. 
Tipično, transdermalni naljepci sadrže nepropustan gornji sloj, sloj ljepljiv jednim pritiskom i zaštitni sloj koji se uklanja te uz to crte za oslobađanje.
Intermediate (4) was dissolved in MEK/dry DMF (2/1) (42 ml, 12 ml/mmol), and the solution containing the quinoline was dropwise added to the reaction mixture, under stirring. 
Međuprodukt (4) je otopljen u MEK/bezvodni DMF (2/1) (42 mL, 12 mL/mmol) 1 otopina koja sadrži kinolin je dokapana u reakcijsku smjesu uz miješanje.
Controlling the other cross head (7, 11) to engage on the leg (4) and to operate in opposite pushing mode or pulling mode; 
Kontroliranje druge pomične poprečne glave (7,11) na način da djeluje na nožicu (4) i da djeluje na način suprotan načinu guranja ili načinu povlačenja;
a lipid compound wherein X is a derivative of a carboxylic acid in the form of a triglyceride; or a lipid compound wherein X is a carboxylate salt. 
(F) lipidnog spoja pri čemu X je derivat karboksilne kiseline u obliku triglicerida; ili (G) lipidnog spoja pri čemu X je sol karboksilata.
mg of ET-743 were added to a compounding glass vessel and dissolved by magnetical stirring in ⅔ volume (90 ml) of the potassium phosphate solution for approximately 1 h (dissolution was checked visually). 
7.85 mg ET-743 dodano je u staklenu posudu za miješanje i otopljeno magnetnim miješanjem u 2/3 zapremine (90 ml) otopine kalijfosfata približno 1 sat (otapanje je provjeravano vizualno).
The nucleic acid molecule according to claim 21, which is RNA. 
Vektor naznačen time da sadrži molekulu nukleinske kiseline prema zahtjevu 8.
The formulation of paragraph 9 wherein the amino acid is at a concentration range of about 0.5 mM to about 300 mM. 
Formulacija prema zahtjevu 6, naznačena time da je amino kiselina u koncentraciji od oko 0.5 mM do oko 300 mM u otopini.
A compound according to claim1, of the formula wherein said compound is selected from the group consisting of: 
[image] gdje je navedeni spoj odabran iz skupine koja se sastoji od sljedećih:
A parasiticidal composition according to claim 2, wherein P and Q are each N; V is C-R8; W is C-R9; 
Paraziticidni sastav prema zahtjevu 2, naznačen time, da svakiod Pi Qje N; V je C-Rg; W je C-Rg;
CRL-9096] when expressed therein; wherein said PankoMab molecule composition is obtainable at a higher yield by producing it in the host cell NM-H9D8 compared to a PankoMab molecule composition isolated from CHOdhfr- [ATCC No. 
CRL-9096 (CHOdhfr-) kada se tamo eksprimira; gdje se navedeni pripravak s molekulom PankoMab može načiniti uz veći prinos njegovom proizvodnjom u DSM ACC 2806 (NM-H9D8) kao stanici domaćinu u usporedbi s pripravkom s molekulom PankoMab izoliranom iz ATCC No.
The method according to claim 1, wherein said vector further comprises one or more DNA sequences coding for regulatory elements selected from 5′UTRs, introns, 3′UTRs, mRNA 3′ end processing sequences, polyadenylation sites, and internal ribosome entry sequences (IRES). 
Upotreba prema zahtjevu 1 ili 2, naznačena time da navedeni vektor nadalje sadrži jednu ili više DNA sekvenci kodiranja za regulatorne elemente koji se biraju iz S'UTR, introna, 3 UTR, mRNA 3' završne obrade sekvence, poliadenilacijskog mjesta, i unutarnjih ribosomskih ulaznih sekvenci (IRES).
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and component (B1) is selected from the group consisting of azoxystrobin and picoxystrobin. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
The therapeutic nanoparticle of any one of claims 1 to 14 or a pharmaceutical composition according to claim 15 for use in treating cancer, preferably wherein the cancer is selected from the group consisting of chronic myelogenous leukemia, chronic myelomonocytic leukemia, hypereosinophilic syndrome, renal cell carcinoma, hepatocellular carcinoma, Philadelphia chromosome positive acute lymphoblastic leukemia, non-small cell lung cancer, pancreatic cancer, breast cancer, a solid tumor, gastrointestinal stromal tumor, head and neck cancer and mantle cell lymphoma. 
Terapijska nanočestica u skladu s bilo kojim od patentnih zahtjeva 1 do 14 ili farmaceutski pripravak u skladu s patentnim zahtjevom 15, naznačeni time što su namijenjeni upotrebi u liječenju raka, gdje se po mogućnosti rak bira iz skupine koju čine kronična mijelogena leukemija, kronična mijelomonocitna leukemija, hipereozinofilni sindrom, karcinom bubrežnih stanica, hepatocelularni karcinom, akutna limfoblastična leukemija pozitivna na filadelfijski kromosom, rak velikih stanica pluća, rak gušterače, rak dojke, čvrsti tumor, tumor gastrointestinalne strome, rak glave i vrata i limfom stanica plašta.
An isolated host cell, wherein said host cell is a yeast cell selected from the group consisting of Saccharomyces cerevisiae, Saccharomyces bulderi, Saccharomyces barnetti, Saccharomyces exiguus, Saccharomyces uvarum, Saccharomyces diastaticus, Kluyveromyces lactis, Kluyveromyces marxianus, and Kluyveromyces fragilis, and said host cell is transformed with a nucleic acid expression construct comprising: a nucleic acid sequence encoding a Clostridium phytofermentans xylose isomerase (XI), having an amino acid sequence that is at least 95% identical to the amino acid sequence SEQ ID NO: 1, and said nucleic acid sequence being operatively linked to a promoter allowing for the expression of the Clostridium phytofermentans xylose isomerase (XI) in the cell; or 
slijed nukleinske kiseline koji kodira prokariotsku ksiloza izomerazu (XI), pri čemu ksiloza izomeraza (XI) potječe iz Clostridium phytofermentans i obuhvaća slijed aminokiselina koji je najmanje 95% identičan, poželjno 99% identičan prema slijedu aminokiselina SEQ ID NO. 1, promotor koji je operativno povezan sa slijedom nukleinske kiseline koji omogućava ekspresiju ksiloza izomeraze (XI) u stanici, pri čemu ekspresija ekspresijskog konstrukta nukleinske kiseline daje stanici mogućnost izravnog izomeriziranja ksiloze u ksilulozu, pri čemu je stanica eukariotska stanica, i pri čemu je stanica transformirana molekulom nukleinske kiseline kako je definirano u patentnim zahtjevima 1 do 5.
Distillation under reduced pressure afforded intermediate 13 as a yellow liquid (19.13 g, 80%). 
Destilacija pod sniženim pritiskom je dala Intermedijer 13 kao žutu tekućinu (19.13 g, 80%).
one or more soft-gel capsules housed within said outer shell, each comprising palonosetron and one or more pharmaceutically acceptable excipients; 
jednu ili više mekanih gel kapsula smještenih unutar navedenog vanjskog omotača, pri čemu svaka sadrži palonosetron i jedan ili više farmaceutski prihvatljivih inertnih punitelja;
Thus, in certain embodiments, the present invention provides a method including the steps of: forming polypropiolactone at a first location; isolating at least some of the polypropiolactone; and dispatching at least some of the isolated polypropiolactone to a second location for pyrolysis to liberate acrylic acid. 
Postupak proizvodnje akrilne kiseline, naznačen time što se postupak sastoji u koracima: dobivanja polipropiolaktona na prvoj lokaciji, koje se sastoju u stavljanju u kontakt B-propiolaktona s katalizatorom polimerizacije koji sadrži akrilatni anion; izdvajanja u najmanju ruku dijela polipropiolaktona; i piroliziranja u najmanju ruku dijela izdvojenog polipropiolaktona kako bi se oslobodilo akrilnu kiselinu na drugoj lokaciji.
MgSO4), treated with decolorizing carbon and evaporated under vacuum to yield an off-white solid, which was recrystallized from 400 ml. of hot ethyl acetate-pentane (156.8 g., 41% yield, m.p. 
MgSO,), tretira sa ugljenom za obezbojavanje i ispari u vakuumu tako da se dobiva bjeličasta supstancija koja se rekristalizira iz 400 ml. vrućeg etilacetata-pentana (156.8 g., 41% prinos, t.t. 100-102%C, elementarna analiza izračunato: 62.21% C; 3.21% H; 28.25% C1; nađeno: 62.17% C; 3.46% H; 28.06% C1).
Dosage form according to claim 5, which contains an amount of pantoprazole magnesium dihydrate, which corresponds to 80 mg of pantoprazole (free acid). 
Dozirni oblik prema zahtjevu 9, naznačen time, da sadrži količinu pantoprazol magnezij dihidrata, koja predstavlja 40 ili 80 mg pantoprazola (slobodna kiselina).
In some cases, angle a2 has a value within a range from about 10 degrees to about 60 degrees. 
Eozin-Y je prisutno u dovoljnoj količini da se dobiju koncentracije od oko 10 uM do oko 50 uM u uvjetima bojenja.
The cells were harvested by centrifugation (1250 rpm for 5 min at 20° C.) and washed with 2 mL ice-cold phosphate-buffered saline (PBS) containing 2% FBS, then stained with 10 uL phycoerythrin-conjugated anti-CD11b antibody or 10 uL phycoerythrin-conjugated isotype control antibody. 
Žetva stanica izvršena je centrifugiranjem (1250 okr u 5 min kod 20% €) a isprane su sa 2 ml ledeno hladnog fosfatnog pufera HR P20090134 T3 (PBS) koji sadrži 2% FBS, a zatim obojeni sa 10 uL phycoerytrin-konjugiranim anti-CD 11b antitijelom ili 10 uL phycoerytrin-konjugiranim izotip kontrol antitijelom.
The pyridone derivative, or a salt thereof, according to claim 1, wherein ring A in the formula (I) represents an aryl or a heteroaryl. 
Derivat piridona ili njegova sol prema patentnom zahtjevu 1, naznačena time da je prsten A u formuli (I) arili ili heteroaril.
The composition of claim 3 wherein the acid functional acrylate copolymer has a number average molecular weight under 10,000, preferably between 2,000 and 6,000. 
Sastav prema zahtjevu 3, naznačen time da kiselo-funkcionalni akrilat-kopolimer ima brojčano srednju molekularnu težinu ispod 10.000, u prednosti između 2.000 1 6.000.
The vaporizer device (100) of claim 1, wherein the susceptor material of the wick element (400, 500, 600) is such that heat is generated by the wick element (400, 500, 600) based on eddy currents generated in the susceptor material and based on movement of magnetic domain walls of the susceptor material. 
Uređaj za vaporizaciju (100) prema zahtjevu 1, naznačen time, da je prijemčiv materijal fitilja (400, 500, 600) takav, da se toplina proizvodi preko fitilja (400, 500, 600) na bazi vrtložnih struja koje se proizvode u prijemčivom materijalu 1 na bazi pomicanja magnetskih stijenki domene prijemčivog materijala.
A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 
Farmaceutska smjesa koja sadrži terapijski učinkovitu količinu spoja iz zahtjeva 1 1 farmaceutski prihvatljiv nosač ili punilo.
The method of claim 1, wherein said compound is represented by the structure of formula IX: 
U LS 5. Spoj iz zahtjeva 1, okarakteriziran strukturnom formulom IX:
A vertically expanding bag (1900), comprising: 
Torba koja se može izduljiti po visini (1900), a obuhvaća -
Pregnenolone or a pharmaceutical salt thereof for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; cardiovascular diseases; nephropathies; spasticity; osteoporosis; cannabis addiction, dependence, abuse, intoxication and relapse related disorders; cannabis and derived products use, cannabis and derived products abuse, cannabis and derived products toxicity and cannabis and derived products induced psychosis; pain; skin fibrotic diseases. 
uz uvjet da u formulama B, D i E kada je veza između C3 i R1 jednostruka, R1 je u poziciji B, za uporabu u liječenju patološkog stanja ili poremećaja izabranog iz grupe koja se sastoji od poremećaja mjehura ili gastriontestinalnih poremećaja, upalnih bolesti, kardiovaskularnih bolesti, nefropatija, glaukoma, spastičnosti, raka, osteoporoze, metaboličkih poremećaja, pretilosti, loše navike, ovisnosti, zlouporabe i poremećaja povezanih s relapsom, psihijatrijskih i neuroloških poremećaja, neurodegenerativnih poremećaja, autoimunog hepatitisa i encefalitisa, boli i kožnih upalnih i fibroznih bolesti.
<400> 22 Pertuzumab, Trastuzumab, and carboplatin-based chemotherapy for use in neoadjuvant treatment of early-stage HER2-positive breast cancer in a patient, wherein the early-stage HER2-positive breast cancer has not spread beyond the breast or the axillary lymph nodes and wherein the carboplatin-based chemotherapy comprises Docetaxel and Carboplatin. 
Kemoterapija na bazi pertuzumaba, trastuzumaba i karboplatina, naznačena time, da se upotrebljava u neoadjuvantnom liječenju ranog stadija HER2-pozitivnog raka dojke kod pacijenata kod kojih se HER2-pozitivni rak dojke u ranom stadiju nije proširio izvan dojke ili aksilarnih limfnih čvorova te time, da kemoterapija na bazi karboplatina obuhvaća docetaksel 1 karboplatin.
The method of claim 1, wherein the cation exchange resin is regenerated in acid form, and/or wherein the anion exchange resin is regenerated in alkali form. 
Postupak sukladno bilo kojem od zahtjeva 1 do 9, pri čemu je smola za izmjenu kationa regenerirana u obliku vodika, a smola za izmjenu aniona je regenerirana u obliku hidroksila.
wherein the antibody or fragment comprises a variable heavy chain (VH) in which CDR1 comprises or consists of the amino acid sequence of: 
Xaje Vili LL pri čemu protutijelo ili fragment sadrži varijabilni teški lanac (VH) u kojem CDRI sadrži ili se sastoji od sekvence amino kiselina:
The method of claim 5, wherein said regression model further correlates outcome with one or more clinical variables. 
(iv) navedeni model dodatno korelira ishod s jednom ili više kliničkih varijabli.
A Polypeptide which is a mutant of an adenylate cyclase protein (mutant polypeptide) and whose amino acid sequence comprises or consists of one of the following sequences: 
Polipeptid čija aminokiselinska sekvenca obuhvaća ili se sastoji od jedne od sljedećih sekvenci:
Another object of the present invention is to provide an IGBT/FET-based device, system and method that may be used for the following: controllers for refrigerators, freezers, air conditioners, AC electric motors and AC voltage; single, bi- and poly-phase whole house energy savings devices; commercial and industrial energy savings devices; and AC voltage regulators. 
Sustav za uštedu energije iz zahtjeva 1, gdje je uređaj za uštedu energije izveden tako da se koristi za regulatore hladnjaka; zamrzivača; klima uređaja; AC električne motore i AC napon; jedno, bi -ili poli fazne uređaje za uštedu energije cijele kuće; uređaje za uštedu komercijalne te industrijske energije; ili regulatore AC napona.
The method for processing cocoa beans or nibs according to claims 5 to 9, wherein the pre-dried solid phase obtained after step (e1) has a water content of 3 to 7% by weight, and/or wherein the cocoa powder obtained after step (e2) has a water content of less than 3% by weight. 
Postupak obrade zrna kakaa ili komadića zrna kakaa u skladu s patentnih zahtjeva 5 do 9, naznačen time što predosušena čvrsta faza dobivena nakon koraka (e1) ima sadržaj vode od 3 do 7%, težinski, i/ili gdje kakao u prahu dobiven nakon koraka (e2) ima sadržaj vode manji od 3%, težinski.
The method according to claim 10, further comprising crimping the connector housing while forcing metal contact plates into conductive engagement with respective ones of the plurality of wires and shearing off the thickened portion of the forward end wall and the projecting ends of the wires. 
Postupak prema zahtjevu 8, naznačen time da nadalje sadrži prešanje kućišta konektora dok prisiljava kontaktne oštrice (36) u provodni spoj s odgovarajućom množinom žica skidanjem zadebljanog vanjskog dijela (100) zajedno sa žicama sadržanim u njemu.
The pharmaceutical composition according to claim 1 or 2, wherein the at least one peptide includes non-peptide bonds. 
peptida u skladu s a), pri čemu navedeni peptid uključuje nepeptidne veze, i
The isolated nucleic acid molecule of claim 1, 4, 7, 10, 13, or 14, wherein the antibody-like binding protein is bispecific and capable of binding two different antigen targets. The isolated nucleic acid molecule of claim 23, wherein the two different antigen targets are selected from the group consisting of IL4 and IL13, IGF1R and HER2, IGF1R and EGFR, EGFR and HER2, BK and IL13, PDL-1 and CTLA-4, CTLA4 and MHC class II, IL-12 and IL-18, IL-1a and IL-1B, TNFa and IL12/23, TNFa and IL-12p40, TNFa and IL1B, TNFa and IL-23, and IL17 and IL23. 
Protutijelu sličan vezivni protein prema bilo kojem od zahtjeva 1, 2, 5 ili 6, naznačen time da vezivni peptid je bispecifičan i može vezati dva različita antigenska cilja, pri čemu, poželjno, dva različita antigenska cilja se biraju iz skupine koju čine ILA i 1L13, IGFIR i HER2, IGFIR i EGFR, EGFR i HER2, BK i IL13, PDL-1 i CTLA-4, CTLA4 1 MHC razred II, IL-12 i 1L-18, IL-1aiIL-18, TNFa.i IL12/23, TNFa i IL-12p40, TNFa.i IL18, TNFa i IL- 23,11L1711L23.
A salt according to claim 6, for use as a medicament for treating or preventing an AB-related pathology, wherein said AB-related pathology is Down's syndrome, a B-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration. 
Sol prema zahtjevu 6, naznačena time da je za uporabu kao lijek za liječenje ili sprječavanje AB-povezanih patologija, pri čemu navedena ARB-povezana patologija je Downov sindrom, B-amiloidna angiopatija, cerebralna amiloidna angiopatija, nasljedno cerebralno krvarenje, poremećaj povezan sa slabljenjem kognitivnih sposobnosti, MCI ("blagi kognitivni poremećaj"), Alzheimerove bolesti, gubitak pamćenja, simptomi pomanjkanja pažnje povezani s Alzheimerovom bolesti, neurodegeneracija povezana s Alzheimerovom bolesti, demencija miješanog vaskularnog podrijetla, demencija degenerativnog porijekla, pred-senilna demencija, senilna demencija, demencija povezana s Parkinsonovom bolesti, progresivna supranuklearna paraliza ili degeneracija bazalnog moždanog korteksa.
The composition for use according to claim 1, wherein the FSD is hypoactive sexual desire disorder (HSDD) A composition comprising trazodone, bupropion, and a pharmaceutically acceptable carrier for use in the treatment of male sexual dysfunction (MSD) in a subject. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da FSD je poremećaja hipoaktivne seksualne želje (HSDD) Pripravak koji sadrži trazodon, bupropion, i farmaceutski prihvatljiv nosač naznačen time da je za uporabu za liječenje muške seksualne disfunkcije (MSD) kod subjekta.
A compound of the formula (SEQ ID No:2) wherein X is selected from the group consisting of H, F, Cl, Br, and I; 
Spoj formule [image] (SEQ ID br. 2) naznačen time, da se X odabire iz skupine koja se sastoji od H, F, Cl, Br i I;
An immunogenic composition according to any preceding claim wherein one or more or all carrier proteins is selected from the group consisting of DT, CRM197, TT, Fragment C, dPly, PhtA, PhyB, PhtD, PhtE, PhtDE OmpC, PorS and Haemophilus influenzae Protein D for use in the treatment or prevention of diseases caused by Streptococcus pneumoniae infection by serotype 19A strains. 
Imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što je svaki saharid iz kapsule bakterije Streptococcus pneumoniae konjugiran s proteinskim nosačem kojeg se neovisno bira iz skupine koju čine tetanusni toksoid (TT), difterijski toksoid (DT), CRM197, fragment C tetanusnog toksoida (TT), PhtD, fuzije PhtDE, detoksicirani pneumolizin i protein D.
The process according to claim 1, wherein the ground calcium carbonate particles and/or the precipitated calcium carbonate particles have a weight median particle diameter d50 value of from 0.1 to 50 um, measured according to the sedimentation method. The process according to claim 1, wherein the ground calcium carbonate particles and/or the precipitated calcium carbonate particles have a weight median particle diameter d50 value of from 0.1 to 25 um, measured according to the sedimentation method. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da čestice prirodnog kalcijevog karbonata i/ili čestice taložnog kalcijevog karbonata imaju vrijednost medijana volume raspodjele promjera čestica d50 od 0.1 do 50 µm, poželjno od 0.1 do 25 µm, poželjnije od 0.1 do 15 µm i najpoželjnije od 0.5 do 5 µm, izmjereno prema postupku sedimentacije.
By applying said equipment pellets can be produced directly, within only a few hours from a suitable powder mixture. 
Primjenom navedenog uređaja granule se mogu načiniti izravno, u samo nekoliko sati, iz odgovarajuće praskaste smjese.
In like manner to that described in Example 7 A-D the named compound (cis-racemate) was prepared from 3-trifluoromethyl-benzophenone (m.p. 
Na sličan način s onim u primjeru 7 A-D napravljen je imenovani spoj (cis-racemat) iz 3-trifluorometil-benzofenona (tt.
reacting the compound of the Formula VII with a suitable chlorinating agent in the presence of a suitable base and a suitable solvent, wherein the reaction is carried out by: 
(g) reakciju spoja formule VII sa prikladnim agensom za kloriranje u prisutnosti prikladne baze i prikladnog otapala, gdje se reakcija provodi uz:
In addition to the encapsulated nucleic acid, one or more therapeutic or diagnostic agents may be included in the transfer vehicle. 
Nosač transfera prema bilo kom od zahtjeva 2 do 8, naznačen time što nosač transfera nadalje sadrži jedno ili više terapeutskih ili dijagnostičkih sredstava.